Opinion
Video
Communication of Treatment Options for High-Risk NMIBC
Author(s):
Experts discuss how they communicate various treatment options for non–muscle-invasive bladder cancer (NMIBC) with patients and health care professionals.
Video Player is loading.
Video content above is prompted by the following:
- How do you communicate various options for NMIBC with patients and healthcare professionals?
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Related Videos
Approaching Corticosteroid Selection With Abiraterone in Patients With High-Risk Localized or Locally Advanced Prostate Cancer
Incorporating Micronized Abiraterone and Low-Fat Meal Dosing: Monitoring Efficacy and Tolerability
The Growing Call for Combination Therapy in NMIBC Treatment
Optimizing NMIBC Treatment Through Sequencing and Patient Preference
Managing Abiraterone Intolerance: Alternative Dosing Strategies in Practice
Decision-Making and Multidisciplinary Counseling for Nodal Involvement on PSMA PET
Rethinking First-Line Treatments: Will BCG Continue to Be the Standard in NMIBC?
In the Pipeline: Novel Treatment Delivery Methods for NMIBC
RX Review: Implementing mitomycin for LG-IR-NMIBC in clinical practice
RX Review: TURBT vs chemoablation for low-grade, intermediate-risk NMIBC
Related Content
